For example, a new study found that the selective COX-2 inhibitor celecoxib can be used in vitro, synergistically enhancing the inhibitory effect of sorafenib on cancer cell growth and AKT activation and inducing cancer cell apoptosis [70]. Here, AKT1 is linked to cancer.